You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

tislelizumab

Showing 26 - 50 of 200
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Esophageal Cancer Trial (Tislelizumab, Radiation, Paclitaxel)

Not yet recruiting
  • Esophageal Cancer
  • Tislelizumab
  • +3 more
  • (no location specified)
Nov 18, 2022

Esophageal Squamous Cell Carcinoma Trial in Wuhan (Intensity-modulated radiotherapy (IMRT), Tislelizumab, Cisplatin)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • Intensity-modulated radiotherapy (IMRT)
  • +3 more
  • Wuhan, Hubei, China
    Renmin hosptial of Wuhan University
Jun 16, 2023

Metastatic Cervical Cancer Trial (Tislelizumab, Sitravatinib)

Not yet recruiting
  • Metastatic Cervical Cancer
  • (no location specified)
Jan 31, 2023

Oral Squamous Cell Carcinoma Trial (Tislelizumab, Albumin paclitaxel, Cisplatin)

Not yet recruiting
  • Oral Squamous Cell Carcinoma
  • Tislelizumab
  • +3 more
  • (no location specified)
May 7, 2023

Colorectal Liver Metastases Trial in Beijing (Tislelizumab, Regorafenib, HAIC)

Recruiting
  • Colorectal Liver Metastases
  • Tislelizumab
  • +2 more
  • Beijing, Beijing, China
  • +1 more
May 25, 2023

Melanoma Trial in Shanghai (Tislelizumab, Lenvatinib, Cryoablation)

Recruiting
  • Melanoma
  • Tislelizumab
  • +2 more
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Nov 8, 2022

Pancreatic Cancer Trial in Baltimore (Tislelizumab, SX-682)

Not yet recruiting
  • Pancreatic Cancer
  • Baltimore, Maryland
    Johns Hopkins SKCCC
Jan 23, 2023

Gastric Cancer Stage IV Trial (Oxaliplatin, Levo-Leucovorin, 5-fluorouracil)

Not yet recruiting
  • Gastric Cancer Stage IV
  • (no location specified)
Nov 13, 2022

Pancreatic Cancer Trial in New York (Canakinumab, Tislelizumab, Nab-Paclitaxel)

Recruiting
  • Pancreatic Cancer
  • New York, New York
  • +2 more
Aug 2, 2023

Gastric Cancer, Gastroesophageal-junction Cancer Trial in Wuhan, Nanjing, Taiyuan (Tislelizumab, S-1, Oxaliplatin)

Not yet recruiting
  • Gastric Cancer
  • Gastroesophageal-junction Cancer
  • Tislelizumab
  • +4 more
  • Wuhan, Hubei, China
  • +2 more
Jan 16, 2023

Immunotherapy Trial (Tislelizumab, Capecitabine, oxaliplatin)

Not yet recruiting
  • Immunotherapy
  • Tislelizumab
  • +4 more
  • (no location specified)
Jul 28, 2022

Colorectal Cancer, Microsatellite Stable Colorectal Carcinoma Trial in Shanghai (Vitamin E, Fruquintinib, Tislelizumab)

Not yet recruiting
  • Colorectal Cancer
  • Microsatellite Stable Colorectal Carcinoma
  • Vitamin E
  • +2 more
  • Shanghai, Shanghai, China
    270 Dongan Road, Fudan University Shanghai Cancer Center
Mar 5, 2023

Renal Cell Carcinoma, Melanoma, Non Small Cell Lung Cancer Trial (HFB200603, Tislelizumab)

Not yet recruiting
  • Renal Cell Carcinoma
  • +4 more
  • (no location specified)
Mar 15, 2023

Solid Tumor, Classic Hodgkin Lymphoma Trial in China (IMM01, Tislelizumab)

Recruiting
  • Solid Tumor
  • Classic Hodgkin Lymphoma
  • Hangzhou, China
  • +4 more
Apr 18, 2023

Metastatic Triple-negative Breast Cancer Trial in Wuhan (Surufatinib, Tislelizumab)

Not yet recruiting
  • Metastatic Triple-negative Breast Cancer
  • Wuhan, Hubei, China
    Tongji Hospital Affiliated of Tongji Medical College Huazhong Un
Feb 27, 2023

NSCLC Trial in Zhengzhou (Tislelizumab)

Active, not recruiting
  • NSCLC
  • Tislelizumab
  • Zhengzhou, Hennan, China
    The First Affiliated Hospital of Zhengzhou University
Oct 31, 2022

Immunotherapy, Gastrict Cancer Trial in Fuzhou (Tislelizumab, Apatinib Mesylate, oxaliplatin)

Recruiting
  • Immunotherapy
  • Gastrict Cancer
  • Tislelizumab
  • +3 more
  • Fuzhou, China
    Fujian cancer hospital
Jan 17, 2023

Muscle Invasive Bladder Cancer, Urothelial Carcinoma Trial in Tianjin (Tislelizumab, Nab paclitaxel)

Active, not recruiting
  • Muscle Invasive Bladder Cancer
  • Urothelial Carcinoma
  • Tislelizumab
  • Nab paclitaxel
  • Tianjin, Tianjin, China
    Tianjin Medical University Second Hospital
Nov 23, 2022

Advanced Squamous Non-Small-Cell Lung Cancer Trial (Trilaciclib, Carboplatin, Paclitaxel)

Not yet recruiting
  • Advanced Squamous Non-Small-Cell Lung Cancer
  • (no location specified)
Jun 11, 2023

NSCLC, Consolidation Immunotherapy, Radiotherapy or Sequential Chemoradiation Trial in Beijing (Tislelizumab)

Recruiting
  • Non-small Cell Lung Cancer
  • +2 more
  • Tislelizumab
  • Beijing, China
    Peking University Cancer Hospital and Institute
Mar 4, 2023

Immunotherapy Gastrict Cancer Trial (Tislelizumab, apatinib, oxaliplatin)

Not yet recruiting
  • Immunotherapy Gastrict Cancer
  • Tislelizumab
  • +3 more
  • (no location specified)
Jan 17, 2023

Head Neck Cancer Trial in Chengdu, Tianjin (Tislelizumab, Pulse radiation)

Recruiting
  • Head and Neck Cancer
  • Tislelizumab
  • Pulse radiation
  • Chengdu, Sichuan, China
  • +1 more
Oct 25, 2022

Solid Tumors Trial (BGB-B167, Tislelizumab)

Not yet recruiting
  • Solid Tumors
  • (no location specified)
Dec 1, 2022

Advanced HCC, Other Solid Tumors Trial in Shanghai (KD6001, Tislelizumab, Bevacizumab)

Not yet recruiting
  • Advanced HCC
  • Other Solid Tumors
  • Shanghai, China
    Zhongshan Hospital
Jun 13, 2023

NSCLC, Stage III Trial in Beijing (Tislelizumab, Pemetrexed (Nonsquamous NSCLC) or Paclitaxel/Nab-paclitaxel(Squamous NSCLC),

Recruiting
  • NSCLC, Stage III
  • Tislelizumab
  • +2 more
  • Beijing, Beijing, China
    Beijing Tsinghua Chang Gung Hospital
Nov 4, 2022